Rezolute’s Stock Rises on Promising Interim Phase III Tumour HI Data

Rezolute's Ersodetug Shows Promising Interim Phase III Data in Tumour HI

Rezolute announced promising interim Phase III data for its drug ersodetug in patients with tumour hyperinsulinism (HI), causing its stock to rise over 10%. In the ongoing open-label study (NCT06881992), six of eight treated patients met the primary endpoint, achieving at least a 50% reduction from baseline in intravenous glucose requirements (GIR) within eight weeks. All six also completely discontinued intravenous glucose requirements. The drug was well-tolerated with no reported drug-related adverse events. Topline results for the fully enrolled study are anticipated in the second half of 2026, with continued engagement with the FDA.

• Interim results from Rezolute's Phase III trial of ersodetug in tumour hyperinsulinism demonstrated significant efficacy. Six out of eight patients treated achieved the primary endpoint, showing at least a 50% reduction in intravenous glucose requirements (GIR) within eight weeks. Crucially, all six responders also achieved complete discontinuation of intravenous glucose requirements, indicating a strong clinical impact in managing hypoglycemia.
• The monoclonal antibody ersodetug exhibited a favorable safety profile in both the pivotal and open-label extension phases of the study. No drug-related adverse events or other safety findings have been reported to date, suggesting good tolerability for patients with tumour HI. This positive safety data supports the potential for ersodetug as a treatment option for this rare disease.
• Following the announcement of these positive interim data, Rezolute's stock on the Nasdaq exchange surged by 10.8%, with further pre-market gains estimated. This positive market reaction contrasts sharply with the company's previous stock crash after the sunRIZE trial failure. The company expects to release topline results for the current open-label study in the second half of 2026 and plans ongoing discussions with the US FDA.

Addressing the Unmet Need in Tumour Hyperinsulinism

Current treatment approaches for tumor hyperinsulinism face significant diagnostic and therapeutic obstacles that complicate patient management. These challenges span from accurate disease identification to effective long-term treatment strategies, particularly given the heterogeneous nature of conditions causing endogenous hyperinsulinemic hypoglycemia.

• Diagnostic complexity and differential challenges: Diseases causing endogenous hyperinsulinemic hypoglycemia present with similar symptoms and biochemical abnormalities despite having different treatment requirements and prognoses, making differential diagnosis crucial but challenging for clinicians managing these patients.

• Risk of inappropriate invasive procedures: Insulin autoimmune syndrome should be considered in patients with unexplained hyperinsulinemic hypoglycemia to avoid unnecessary invasive evaluation for insulinoma, as patients may experience markedly elevated insulin concentrations reaching 19,300 μU/mL with high insulin autoantibody titers.

• Chemotherapy resistance mechanisms: The first-line chemotherapeutic agent temozolomide for metastatic pancreatic neuroendocrine tumors faces significant resistance challenges primarily mediated by the DNA repair enzyme O-methylguanine-DNA methyltransferase (MGMT), which limits long-term efficacy in many patients.

• Systemic toxicity burden: Temozolomide treatment causes substantial systemic toxicity in patients with pancreatic neuroendocrine tumors, creating additional management challenges beyond the primary therapeutic goals.

• Surgical limitations due to metastatic disease: Pancreatic neuroendocrine tumors demonstrate high rates of metastasis, rendering many patients ineligible for surgical resection, which remains the most definitive treatment approach.

• Inadequate conservative management: In insulin autoimmune syndrome cases, dietary modification with frequent small meals and carbohydrate restriction may be insufficient for managing frequent nocturnal and postprandial hypoglycemic episodes, with plasma glucose levels dropping as low as 27 mg/dL, requiring additional prednisolone therapy.

Ersodetug's Interim Phase III Data: Design and Efficacy

The available literature for tumor hyperinsulinism primarily consists of case reports, small retrospective studies, and preclinical work rather than formal randomized controlled trials. These studies provide limited but valuable insights into treatment approaches and endpoints for insulinoma management.

Ersodetug's Safety Profile and Path Forward in Tumour HI

Ersodetug demonstrated a favorable safety profile in a global, open-label phase 2b study (NCT04538989) evaluating its use in congenital hyperinsulinism (cHI), a rare pediatric disease characterized by dysregulated insulin secretion and severe, persistent hypoglycemia. The study enrolled 23 patients aged 2 years and older (average age 6.7 years) who had persistent hypoglycemia despite standard-of-care therapies, with 87% receiving medications and 17% having undergone previous pancreatectomy. Participants received add-on ersodetug at escalating dose levels between 3 and 9 mg/kg intravenously bi-weekly for 8 weeks across 4 sequential dose cohorts.

The safety outcomes across all dose cohorts were notably favorable, with no deaths, adverse drug reactions, study withdrawals, or dose-limiting toxicities reported during the 8-week treatment period. Ersodetug was generally well tolerated across all participants, suggesting a benign safety profile in this pediatric population with congenital hyperinsulinism. The drug demonstrated predictable, dose-proportional pharmacokinetics across the studied dose range, indicating consistent and manageable drug exposure characteristics.

Based on the available published data, ersodetug's safety evaluation has been limited to congenital hyperinsulinism as the sole studied indication. The open-label design of the phase 2b study provides preliminary safety data, though no direct placebo-controlled comparison was available to establish a comprehensive safety profile. The absence of safety signals in this vulnerable pediatric population with a serious metabolic disorder provides encouraging preliminary evidence for ersodetug's tolerability, though broader safety data across additional indications and larger patient populations would be needed for a more complete safety assessment.

Ersodetug's Interim Data: A New Horizon for Hyperinsulinism Treatment

The recent interim Phase III data for ersodetug in tumour hyperinsulinism marks a potentially pivotal moment for patients suffering from this challenging condition. Tumour hyperinsulinism leads to severe, persistent hypoglycemia, often necessitating continuous intravenous glucose and, in many cases, surgical intervention. While somatostatin analogues have been used, a significant unmet need remains for effective, non-surgical treatments. Ersodetug offers a novel approach, acting as an insulin receptor antibody to allosterically reduce excess insulin action, a mechanism distinct from therapies that aim to suppress insulin secretion.

The early results are compelling: six out of eight patients achieved a substantial reduction in intravenous glucose requirements, with all six completely discontinuing IV glucose within eight weeks. This level of efficacy, coupled with a clean safety profile showing no drug-related adverse events, is highly encouraging. Such strong interim data not only validates the innovative mechanism of insulin receptor antagonism but also suggests ersodetug could become a critical new therapeutic option, potentially sparing patients from invasive surgeries or providing an alternative where current treatments fall short.

However, it is crucial to contextualize these promising findings. The data stems from a small, open-label cohort, and while impressive, the full picture will emerge with the complete Phase III results expected in late 2026. The small sample size means that the observed efficacy and safety may not perfectly translate to a broader patient population. Furthermore, the open-label nature could introduce some bias into the reporting. Long-term safety and the sustained durability of ersodetug's effect beyond the initial assessment period are also key considerations that the full study will need to address. Despite these caveats, the early signals are robust, pointing towards a potential paradigm shift in how tumour hyperinsulinism is managed, offering new hope for patients and their clinicians.